Roche Launches New Metabolite Tests for its Cedex Bio Systems Offering the Most Comprehensive Testing Portfolio for Bioprocess Analytics
Roche has announced the launch of new metabolite-testing reagent sets to determine the concentration of iron and phosphate, two parameters relevant for cell growth and productivity during fermentation processes. The tests are designed for applications in research and bio-manufacturing process development and will allow the measurement of iron (complexed iron /Fe3+ ions) and phosphate on Cedex Bio instruments.
“The new tests ideally expand our metabolite testing portfolio for mammalian cell fermentation analytics. It is currently the most comprehensive portfolio combining iron and phosphate testing with other relevant parameters such as IgG, LDH and other standard metabolites,” said Ruedi Stoffel, Head of Biochemical Reagents and Custom Biotech. “Thanks to their reliability, precision, and ease of use, our Cedex instruments and the new testing portfolio are perfectly designed to optimize process development and monitoring of bio-pharmaceutical production particularly when using chemically defined media. The rapidly increasing customer base of our Cedex instruments will benefit from our continuously expanding testing portfolio.”
The new tests can be easily installed by barcode reading through the customer supporting the flexible testing concept. Offered as liquid-stable formulation, they are ready for use and do not require manual dilution or pipetting steps. With their increased precision, accuracy and long calibration intervals, the new iron and phosphate tests offer cost-effective and convenient testing with less hands-on time for users.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...